Eli Lilly Corp. buy marge
Start price
08.04.17
/
50%
€80.28
Target price
18.04.17
€95.00
Performance (%)
-2.91%
End price
18.04.17
€77.94
Summary
This prediction ended on 18.04.17 with a price of €77.94. With a performance of -2.91%, the BUY prediction for Eli Lilly Corp. by marge closed slightly in the red. marge has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Eli Lilly Corp. | 0.543% | 0.543% | 90.651% | 360.175% |
| iShares Core DAX® | 2.594% | -1.861% | 13.242% | 16.867% |
| iShares Nasdaq 100 | 3.553% | -2.064% | 38.293% | 45.898% |
| iShares Nikkei 225® | 0.687% | -8.704% | 17.510% | 2.760% |
| iShares S&P 500 | 2.209% | -1.988% | 27.632% | 42.955% |
Comments by marge for this prediction
In the thread Eli Lilly Corp. diskutieren
marge stimmt der Buy-Einschätzung von gerihouse zu
marge stimmt am 08.04.2017 der Buy-Einschätzung von gerihouse aber mit dem Kursziel 95€ zu.
Überschrift: weltweit führendes pharma Unternehmen
- Positive catalysts include expected FDA approval of of rheumatoid arthritis drug Olumiant this month, and phase three data from cancer drug abemaciclib at the American Society of Clinical Oncology in June, says the team at Barclays, reiterating their Overweight rating on Eli Lilly (LLY), and boosting the price target to $90.
- They also note recent prescription trends for the likes of Trulicity, Jardiance, and Taltz should support the stock.
(Vom Mitglied beendet)
Stopped prediction by marge for Eli Lilly Corp.
Eli Lilly Corp.
Start price
Target price
Perf. (%)
€98.23
20.12.18
20.12.18
€160.00
04.11.21
04.11.21
138.31%
05.11.21
05.11.21
